104 related articles for article (PubMed ID: 3110794)
1. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine.
Martin AJ; Tebbs VM; Ashford JJ
Pharmatherapeutica; 1987; 5(1):40-9. PubMed ID: 3110794
[TBL] [Abstract][Full Text] [Related]
2. Flupenthixol and fluvoxamine in mild to moderate depression: a comparison in general practice.
Hamilton BA; Jones PG; Hoda AN; Keane PM; Majid I; Zaidi SI
Pharmatherapeutica; 1989; 5(5):292-7. PubMed ID: 2501801
[TBL] [Abstract][Full Text] [Related]
3. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression.
de Jonghe F; Swinkels J; Tuynman-Qua H
Pharmacopsychiatry; 1991 Jan; 24(1):21-7. PubMed ID: 1901418
[TBL] [Abstract][Full Text] [Related]
4. A Belgian multicentre study of fluvoxamine in depressive outpatients.
Brasseur R; Van Moffaert M; Mesotten F; Ansseau M; Uytdenhoef P; Bartholome F
Acta Psychiatr Belg; 1985; 85(5):636-43. PubMed ID: 3937441
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
6. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM
J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
[TBL] [Abstract][Full Text] [Related]
7. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
[TBL] [Abstract][Full Text] [Related]
8. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
[TBL] [Abstract][Full Text] [Related]
10. [The status of fluvoxamine among the antidepressive agents].
Svestka J; Cesková E; Rysánek R; Obrovská V; Kamenická V
Cesk Psychiatr; 1992 Sep; 88(5):209-19. PubMed ID: 1451197
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients.
Rahman MK; Akhtar MJ; Savla NC; Sharma RR; Kellett JM; Ashford JJ
Br J Clin Pract; 1991; 45(4):255-8. PubMed ID: 1810358
[TBL] [Abstract][Full Text] [Related]
13. Fluvoxamine in the treatment of tricyclic-resistant depression.
White K; Wykoff W; Tynes LL; Schneider L; Zemansky M
Psychiatr J Univ Ott; 1990 Sep; 15(3):156-8. PubMed ID: 2123039
[TBL] [Abstract][Full Text] [Related]
14. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
16. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence].
Daléry J; Aubin V
Encephale; 2001; 27(1):71-81. PubMed ID: 11294041
[TBL] [Abstract][Full Text] [Related]
18. Neurotic depression accompanied by somatic symptoms: a double-blind comparison of flupenthixol and diazepam in general practice.
Grillage M
Pharmatherapeutica; 1986; 4(9):561-70. PubMed ID: 3763651
[TBL] [Abstract][Full Text] [Related]
19. [Tricyclic antidepressants dosage and depressed elderly inpatients: a retrospective pharmaco-epidemiologic study].
Ballon N; Siobud-Dorocant E; Even C; Slama F; Dardennes R
Encephale; 2001; 27(4):373-6. PubMed ID: 11686060
[TBL] [Abstract][Full Text] [Related]
20. [Prospective evaluation of antidepressant discontinuation].
Mourad I; Lejoyeux M; Adès J
Encephale; 1998; 24(3):215-22. PubMed ID: 9696914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
